{"id":60900,"date":"2025-03-08T04:02:34","date_gmt":"2025-03-08T03:02:34","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/tiximed-inc-announces-successful-dosing-of-first-cohort-in-the-phase-1-clinical-trial-of-tix100-its-investigational-disease-modifying-treatment-for-type-1-diabetes\/"},"modified":"2025-03-08T04:02:34","modified_gmt":"2025-03-08T03:02:34","slug":"tiximed-inc-announces-successful-dosing-of-first-cohort-in-the-phase-1-clinical-trial-of-tix100-its-investigational-disease-modifying-treatment-for-type-1-diabetes","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/tiximed-inc-announces-successful-dosing-of-first-cohort-in-the-phase-1-clinical-trial-of-tix100-its-investigational-disease-modifying-treatment-for-type-1-diabetes\/","title":{"rendered":"TIXiMED Inc. Announces Successful Dosing of First Cohort in the Phase 1 Clinical Trial of TIX100, its Investigational Disease-Modifying Treatment for Type 1 Diabetes"},"content":{"rendered":"<div>\n<ul class=\"bwlistdisc\">\n<li>\nNo drug associated adverse effects were reported\n<\/li>\n<li>\nOral drug was well tolerated, and no clinically significant findings or safety concerns were noted\n<\/li>\n<li>\nEscalation to the second dose cohort of this single ascending dose study continues per protocol\n<\/li>\n<\/ul>\n<p>BIRMINGHAM, Ala.&#8211;(BUSINESS WIRE)&#8211;TIXiMED Inc. (<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.tiximed.com&amp;esheet=54221421&amp;newsitemid=20250307244371&amp;lan=en-US&amp;anchor=www.tiximed.com&amp;index=1&amp;md5=c8022d59942d66859d2390f4a1f9713e\" rel=\"nofollow\" shape=\"rect\">www.tiximed.com<\/a>), a clinical-stage pharmaceutical company based on the breakthrough discovery that TXNIP plays an important role in the development and progression of diabetes, today announced successful dosing of the first dose cohort in the Phase 1 Single Ascending Dose (SAD) trial of TIX100, its investigational novel oral therapy targeting beta cell health and islet cell function. Additionally, based on the safety review meeting, it was recommended that the randomized, placebo-controlled quadruple-blind clinical trial continue with no modifications and the next cohort escalate to the pre-specified dose level.\n<\/p>\n<p>\n\u201c<i>We are pleased to achieve this significant milestone in the development of TIX100 with this first-in-human trial,\u201d <\/i>said Dr. Anath Shalev, TIXiMED Founder and Chief Scientific Officer. \u201c<i>We look forward to evaluating the findings of the next, higher dose cohorts in the coming months and to a successful completion of the SAD trial later this year,\u201d<\/i> Dr. Shalev added.\n<\/p>\n<p>\n\u201c<i>We have seen increasing recognition of the promise of TIX100 to one day improve the lives of people with type 1 diabetes<\/i>,\u201d said TIXiMED President and Board Chair Mike Goodrich. \u201c<i>This first-in-human trial is the cornerstone of the clinical work we\u2019ve planned to advance this novel therapy. We are very thankful to our investors and partners, including The Helmsley Charitable Trust, who <\/i><a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.businesswire.com%2Fnews%2Fhome%2F20241219802666%2Fen%2FTIXiMED-Announces-a-2.65M-Program-Related-Investment-from-the-Helmsley-Charitable-Trust-to-Initiate-Clinical-Trials-of-Its-Novel-Oral-Therapy-for-Beta-Cell-Survival-and-Function&amp;esheet=54221421&amp;newsitemid=20250307244371&amp;lan=en-US&amp;anchor=made&amp;index=2&amp;md5=a3a934835054c00588fc952ef8031149\" rel=\"nofollow\" shape=\"rect\"><i>made<\/i><\/a><i> a program-related investment in the form of a loan to TIXiMED<\/i>,\u201d Mr. Goodrich concluded.\n<\/p>\n<p>\n<b>About TIXiMED Inc.<\/b>\n<\/p>\n<p>\nTIXiMED is a clinical stage pharmaceutical company dedicated to developing and commercializing a first-of-its kind oral therapy for type 1 diabetes based on TXNIP inhibition. TIXiMED is the exclusive license holder for the patent surrounding TIX100, a novel, small molecule TXNIP inhibitor, and its derivatives, that has been shown to protect against models of type 1 and type 2 diabetes as well as metabolic dysfunction\u2013associated steatotic liver disease. Visit <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.tiximed.com&amp;esheet=54221421&amp;newsitemid=20250307244371&amp;lan=en-US&amp;anchor=www.tiximed.com&amp;index=3&amp;md5=046f83b3c783b60e6741c12674ab2bc3\" rel=\"nofollow\" shape=\"rect\">www.tiximed.com<\/a> for more information.\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\nEmma Bolden<br \/>\n<br \/><a target=\"_blank\" href=\"&#109;&#x61;&#x69;&#108;&#x74;&#x6f;&#58;&#x69;&#x6e;&#102;&#x6f;&#x40;&#116;&#x69;&#x78;&#105;&#x6d;&#x65;&#100;&#x2e;&#x63;&#111;&#x6d;\" rel=\"nofollow\" shape=\"rect\">&#x69;&#110;f&#x6f;&#x40;&#116;i&#x78;&#x69;&#109;e&#x64;&#46;c&#x6f;&#x6d;<\/a><br \/>+1.205.578.1005\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>No drug associated adverse effects were reported Oral drug was well tolerated, and no clinically significant findings or safety concerns were noted Escalation to the second dose cohort of this single ascending dose study continues per protocol BIRMINGHAM, Ala.&#8211;(BUSINESS WIRE)&#8211;TIXiMED Inc. (www.tiximed.com), a clinical-stage pharmaceutical company based on the breakthrough discovery that TXNIP plays an &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/tiximed-inc-announces-successful-dosing-of-first-cohort-in-the-phase-1-clinical-trial-of-tix100-its-investigational-disease-modifying-treatment-for-type-1-diabetes\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-60900","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>TIXiMED Inc. Announces Successful Dosing of First Cohort in the Phase 1 Clinical Trial of TIX100, its Investigational Disease-Modifying Treatment for Type 1 Diabetes - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/tiximed-inc-announces-successful-dosing-of-first-cohort-in-the-phase-1-clinical-trial-of-tix100-its-investigational-disease-modifying-treatment-for-type-1-diabetes\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"TIXiMED Inc. Announces Successful Dosing of First Cohort in the Phase 1 Clinical Trial of TIX100, its Investigational Disease-Modifying Treatment for Type 1 Diabetes - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"No drug associated adverse effects were reported Oral drug was well tolerated, and no clinically significant findings or safety concerns were noted Escalation to the second dose cohort of this single ascending dose study continues per protocol BIRMINGHAM, Ala.&#8211;(BUSINESS WIRE)&#8211;TIXiMED Inc. (www.tiximed.com), a clinical-stage pharmaceutical company based on the breakthrough discovery that TXNIP plays an ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/tiximed-inc-announces-successful-dosing-of-first-cohort-in-the-phase-1-clinical-trial-of-tix100-its-investigational-disease-modifying-treatment-for-type-1-diabetes\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-08T03:02:34+00:00\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tiximed-inc-announces-successful-dosing-of-first-cohort-in-the-phase-1-clinical-trial-of-tix100-its-investigational-disease-modifying-treatment-for-type-1-diabetes\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tiximed-inc-announces-successful-dosing-of-first-cohort-in-the-phase-1-clinical-trial-of-tix100-its-investigational-disease-modifying-treatment-for-type-1-diabetes\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"TIXiMED Inc. Announces Successful Dosing of First Cohort in the Phase 1 Clinical Trial of TIX100, its Investigational Disease-Modifying Treatment for Type 1 Diabetes\",\"datePublished\":\"2025-03-08T03:02:34+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tiximed-inc-announces-successful-dosing-of-first-cohort-in-the-phase-1-clinical-trial-of-tix100-its-investigational-disease-modifying-treatment-for-type-1-diabetes\\\/\"},\"wordCount\":372,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tiximed-inc-announces-successful-dosing-of-first-cohort-in-the-phase-1-clinical-trial-of-tix100-its-investigational-disease-modifying-treatment-for-type-1-diabetes\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tiximed-inc-announces-successful-dosing-of-first-cohort-in-the-phase-1-clinical-trial-of-tix100-its-investigational-disease-modifying-treatment-for-type-1-diabetes\\\/\",\"name\":\"TIXiMED Inc. Announces Successful Dosing of First Cohort in the Phase 1 Clinical Trial of TIX100, its Investigational Disease-Modifying Treatment for Type 1 Diabetes - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"datePublished\":\"2025-03-08T03:02:34+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tiximed-inc-announces-successful-dosing-of-first-cohort-in-the-phase-1-clinical-trial-of-tix100-its-investigational-disease-modifying-treatment-for-type-1-diabetes\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tiximed-inc-announces-successful-dosing-of-first-cohort-in-the-phase-1-clinical-trial-of-tix100-its-investigational-disease-modifying-treatment-for-type-1-diabetes\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tiximed-inc-announces-successful-dosing-of-first-cohort-in-the-phase-1-clinical-trial-of-tix100-its-investigational-disease-modifying-treatment-for-type-1-diabetes\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"TIXiMED Inc. Announces Successful Dosing of First Cohort in the Phase 1 Clinical Trial of TIX100, its Investigational Disease-Modifying Treatment for Type 1 Diabetes\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"TIXiMED Inc. Announces Successful Dosing of First Cohort in the Phase 1 Clinical Trial of TIX100, its Investigational Disease-Modifying Treatment for Type 1 Diabetes - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/tiximed-inc-announces-successful-dosing-of-first-cohort-in-the-phase-1-clinical-trial-of-tix100-its-investigational-disease-modifying-treatment-for-type-1-diabetes\/","og_locale":"en_US","og_type":"article","og_title":"TIXiMED Inc. Announces Successful Dosing of First Cohort in the Phase 1 Clinical Trial of TIX100, its Investigational Disease-Modifying Treatment for Type 1 Diabetes - Pharma Trend","og_description":"No drug associated adverse effects were reported Oral drug was well tolerated, and no clinically significant findings or safety concerns were noted Escalation to the second dose cohort of this single ascending dose study continues per protocol BIRMINGHAM, Ala.&#8211;(BUSINESS WIRE)&#8211;TIXiMED Inc. (www.tiximed.com), a clinical-stage pharmaceutical company based on the breakthrough discovery that TXNIP plays an ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/tiximed-inc-announces-successful-dosing-of-first-cohort-in-the-phase-1-clinical-trial-of-tix100-its-investigational-disease-modifying-treatment-for-type-1-diabetes\/","og_site_name":"Pharma Trend","article_published_time":"2025-03-08T03:02:34+00:00","author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/tiximed-inc-announces-successful-dosing-of-first-cohort-in-the-phase-1-clinical-trial-of-tix100-its-investigational-disease-modifying-treatment-for-type-1-diabetes\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/tiximed-inc-announces-successful-dosing-of-first-cohort-in-the-phase-1-clinical-trial-of-tix100-its-investigational-disease-modifying-treatment-for-type-1-diabetes\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"TIXiMED Inc. Announces Successful Dosing of First Cohort in the Phase 1 Clinical Trial of TIX100, its Investigational Disease-Modifying Treatment for Type 1 Diabetes","datePublished":"2025-03-08T03:02:34+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/tiximed-inc-announces-successful-dosing-of-first-cohort-in-the-phase-1-clinical-trial-of-tix100-its-investigational-disease-modifying-treatment-for-type-1-diabetes\/"},"wordCount":372,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/tiximed-inc-announces-successful-dosing-of-first-cohort-in-the-phase-1-clinical-trial-of-tix100-its-investigational-disease-modifying-treatment-for-type-1-diabetes\/","url":"https:\/\/pharma-trend.com\/en\/tiximed-inc-announces-successful-dosing-of-first-cohort-in-the-phase-1-clinical-trial-of-tix100-its-investigational-disease-modifying-treatment-for-type-1-diabetes\/","name":"TIXiMED Inc. Announces Successful Dosing of First Cohort in the Phase 1 Clinical Trial of TIX100, its Investigational Disease-Modifying Treatment for Type 1 Diabetes - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"datePublished":"2025-03-08T03:02:34+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/tiximed-inc-announces-successful-dosing-of-first-cohort-in-the-phase-1-clinical-trial-of-tix100-its-investigational-disease-modifying-treatment-for-type-1-diabetes\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/tiximed-inc-announces-successful-dosing-of-first-cohort-in-the-phase-1-clinical-trial-of-tix100-its-investigational-disease-modifying-treatment-for-type-1-diabetes\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/tiximed-inc-announces-successful-dosing-of-first-cohort-in-the-phase-1-clinical-trial-of-tix100-its-investigational-disease-modifying-treatment-for-type-1-diabetes\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"TIXiMED Inc. Announces Successful Dosing of First Cohort in the Phase 1 Clinical Trial of TIX100, its Investigational Disease-Modifying Treatment for Type 1 Diabetes"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/60900","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=60900"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/60900\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=60900"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=60900"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=60900"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}